Alkem Laboratories Ltd

Alkem Laboratories Management Change

Alkem Laboratories CFO Nitin Agrawal resigned effective 30 September 2026 for new opportunities. He was also a Key Managerial Personnel of the company.

Alkem Laboratories Debt & Borrowing: ₹593.5 Cr

Alkem Laboratories issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank for a Euro 49.5 Million term loan taken by its subsidiary, Occlutech Holding.

Value

₹593.5 Cr

Alkem Laboratories Product Launch

Alkem launches NeuCeno (cenobamate), an anti-seizure medication for partial-onset seizures in adults, for the first time in India. The once-daily drug is available in six tablet strengths.

Alkem Laboratories Management Change

Alkem Laboratories has appointed Dr. Shubhadeep Sinha as a Senior Management Personnel, effective September 15, 2026. This appointment falls under standard senior management disclosures.

Alkem Laboratories Product Launch

Alkem launched Renocia Exo, a patented exosome-based hair growth serum. It expands the company's dermatology portfolio with a new follicle-support therapy.

Alkem Laboratories Annual General Meeting

Alkem Laboratories Limited concluded its 52nd Annual General Meeting on August 27, 2026. All resolutions proposed in the notice were duly approved by the members.

Alkem Laboratories Capital Structure Change

HDFC Mutual Fund disclosed an acquisition of 25,019 shares of Alkem Laboratories, increasing their aggregate holding to 5.017%. This triggers a mandatory regulatory disclosure.

Alkem Laboratories Investor Presentation: Key Takeaways

Alkem reported Q1FY27 revenue of INR 3,740cr, up 11% YoY. India sales grew 10.3%, while International jumped 16%. EBITDA margin stood at 20.5%. Net profit declined 21.7% due to taxation.

Call

Guides 12% growth

Alkem Laboratories Merger & Restructuring

Alkem Laboratories held an NCLT-convened meeting of equity shareholders to approve the Scheme of Amalgamation with Adroit Biomed Limited. The scheme received majority shareholder approval.

Alkem Laboratories Capacity Expansion: ₹75 Cr Investment

Alkem Laboratories' Board approved a new block at its Baddi manufacturing facility. The company will invest up to ₹75 Crore in this capacity expansion.

Value

₹75.00 Cr

Alkem Laboratories Results Update

Alkem Laboratories reported an 11% revenue growth to ₹3,740.2 Crore for Q1FY27. Net profit stood at ₹520 Crore despite a 21.7% year-on-year decline.

Value

₹3,740 Cr

Alkem Laboratories Q1 FY27 Results: Net Profit ₹521 Cr, Down 22.0% YoY

Alkem Laboratories Ltd reported revenue from operations of ₹3,740 Cr (+10.9% YoY) and net profit of ₹521 Cr (-22.0% YoY) for Q1 FY27.

Key figure

Net profit ₹521 Cr · -22.0% YoY